XRCC2 and colorectal carcinoma: FANCU/XRCC2 is not only a potentially useful predictive biomarker of treatment responses in CRC patients, as already detailed in Section 4 [100,107], but it might also be a promising therapeutic target for the treatment of CRC [145].